Jazz Pharmaceuticals plc

JAZZ

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001232524

None

No letter

6 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $11.7B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	thin data not computable: dilution, distress
Inputs computable	6 of 14
Graded from	filings received through Apr 24, 2026 186 days before the rescan; latest periodic filing 10-Q received Aug 3, 2026
Last close	$205.66 2026-10-26; market equity $13.4B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 24, 2026

Jazz Pharmaceuticals plc is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease - often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering R&D advancements across our robust pipeline of innovative therapeutics. Our lead marketed products, listed below, are approved in countries around the world to improve patient care.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 53.0						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	(3.0%)	9.3%		75.3	74	2025-12-31

Accruals ratio	(14.5%)	(6.6%)	30.6	805	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 74.4					
Twelve-month failure probability	not computable	0.07%			
liabilities and a nearby cover-page share count are required at 2026-06-30					
Altman Z double-prime	not computable	(0.33)			
one or more required annual facts are missing					
Net debt to EBITDA	not computable	1.82x			
EBITDA must exceed $100,000					
Interest coverage	not computable	(4.51x)			
latest aligned inputs end 2011-12-31; latest annual assets end 2025-12-31					
Current ratio	1.86x	2.94x	74.4	832	2025-12-31
Growth and financing, sleeve percentile 58.5					
Revenue growth, three-year compound	5.3%	10.1%	58.7	413	2025-12-31
Free cash flow growth, three-year compound	1.4%	10.9%	70.5	96	2025-12-31
Reinvestment rate	not computable	37.1%			
NOPAT must exceed $100,000					
Asset growth, three years	2.5%	2.1%	46.1	697	2025-12-31
Net share issuance, one year	not computable	2.5%			
prior share count is 57 days earlier					

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	6 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-10-26 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	90.2%	7.7%	86
Distance from 52-week high	(21.4%)	(31.2%)	62
EBIT to enterprise value	(2.7%)	(1.5%)	46
Free cash flow yield	9.7%	(1.0%)	92
Book value to price	0.36	0.28	57
Sales to price	0.32	0.30	51
Composite equity issuance, five years	13.2%	20.5%	44
Relative strength against the sector, log excess return	0.43	(0.14)	86

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Cash, filings, liquidity	
Cash and equivalents	$1.6B
Operating cash flow, four quarters	$1.7B
Months of runway	not finite
Days since last periodic filing	85 (10-Q received Aug 3, 2026)
Median daily dollar volume, 63 sessions	$169.2M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	operating income	us-gaap:OperatingIncomeLoss	-$430.2M	2025-12-31	2026-02-24	10-K	26-000013
2	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$627.9M	2025-12-31	2026-02-24	10-K	26-000013
3	income tax	us-gaap:IncomeTaxExpenseBenefit	-$272.4M	2025-12-31	2026-02-24	10-K	26-000013
4	total debt	us-gaap:LongTermDebt	$5.4B	2025-12-31	2026-02-24	10-K	26-000013
5	book equity	us-gaap:StockholdersEquity	$4.3B	2025-12-31	2026-02-24	10-K	26-000013
6	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$1.4B	2025-12-31	2026-02-24	10-K	26-000013
7	total debt	us-gaap:LongTermDebt	$6.1B	2024-12-31	2026-02-24	10-K	26-000013
8	book equity	us-gaap:StockholdersEquity	$4.1B	2024-12-31	2026-02-24	10-K	26-000013
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$2.4B	2024-12-31	2026-02-24	10-K	26-000013
10	net income	us-gaap:NetIncomeLoss	-$356.1M	2025-12-31	2026-02-24	10-K	26-000013
11	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$1.4B	2025-12-31	2026-02-24	10-K	26-000013
12	assets	us-gaap:Assets	$11.7B	2025-12-31	2026-02-24	10-K	26-000013
13	assets	us-gaap:Assets	$12.0B	2024-12-31	2026-02-24	10-K	26-000013
14	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$41.6M	2025-12-31	2026-02-24	10-K	26-000013
15	operating income	us-gaap:OperatingIncomeLoss	$127.8M	2011-12-31	2014-02-25	10-K	14-000012
16	interest expense	us-gaap:InterestExpense	$1.7M	2011-12-31	2012-02-28	10-K	12-085849
17	current assets	us-gaap:AssetsCurrent	$4.2B	2025-12-31	2026-02-24	10-K	26-000013
18	current liabilities	us-gaap:LiabilitiesCurrent	$2.2B	2025-12-31	2026-02-24	10-K	26-000013
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$4.3B	2025-12-31	2026-02-24	10-K	26-000013
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$4.1B	2024-12-31	2026-02-24	10-K	26-000013
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$3.8B	2023-12-31	2026-02-24	10-K	26-000013
22	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$3.7B	2022-12-31	2025-02-26	10-K	25-000011
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$58.8M	2025-12-31	2026-02-24	10-K	26-000013
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$1.4B	2024-12-31	2026-02-24	10-K	26-000013
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$38.1M	2024-12-31	2026-02-24	10-K	26-000013
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$1.1B	2023-12-31	2026-02-24	10-K	26-000013
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$24.0M	2023-12-31	2026-02-24	10-K	26-000013
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$1.3B	2022-12-31	2025-02-26	10-K	25-000011
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$29.0M	2022-12-31	2025-02-26	10-K	25-000011
30	current assets	us-gaap:AssetsCurrent	$4.6B	2024-12-31	2026-02-24	10-K	26-000013
31	current liabilities	us-gaap:LiabilitiesCurrent	$1.0B	2024-12-31	2026-02-24	10-K	26-000013
32	assets	us-gaap:Assets	$11.4B	2023-12-31	2025-02-26	10-K	25-000011
33	assets	us-gaap:Assets	$10.8B	2022-12-31	2024-02-28	10-K	24-000015
34	shares outstanding	dei:EntityCommonStockSharesOutstanding	62,738,815	2026-04-15	2026-04-24	10-K/A	26-027205
35	shares outstanding	dei:EntityCommonStockSharesOutstanding	61,560,350	2026-02-17	2026-02-24	10-K	26-000013

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.